The target populations for this study were patients with histologically or cytologically confirmed, locally advanced/ metastatic renal cell carcinoma who progressed during or after or intolerant to previous first-line VEGFR-TKI therapy.~A total of about 249-264 patients are planned to be enrolled in the study, among whom about 234 patients are planned to be enrolled in the first part. The patients who are successfully enrolled will be randomly assigned into the investigational arm or the control arm in a 1:1 ratio. The patient who does not meet the enrollment criteria for the first part can be enrolled in the second part of the study. About 15-30 patients are planned to be enrolled in the second part, . The patient who are successfully enrolled will receive Fruquintinib monotherapy.
The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of Fruquintinib in combination with Sintilimab versus axitinib or everolimus montherapy as second-line treatment for locally advanced or metastatic renal cell carcinoma. The second part is a Fruquintinib montherapy factorial cohort study to evaluate the efficacy and safety of Fruquintinib monotherapy as for second-line treatment of locally advanced or metastatic renal cell carcinoma.